natgillin/translations-raw huggingface dataset:
Symptoms: Relative large overdoses (200 mg and 105 mg/day for 3days, respectively) have been associated with either only symptoms of tiredness, weakness and/or diarrhoea or no symptoms.
Simptomi: Sorazmerno veliko preveliko odmerjanje (200 mg dnevno oziroma 105 mg dnevno, tri dni) je bilo povezano bodisi samo s simptomi utrujenosti, šibkosti in/ali driske bodisi je bilo brez simptomov.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Simptomi: Najizrazitejša znaka prevelikega odmerjanja telmisartana sta hipotenzija in tahikardija; poročali so tudi o bradikardiji, omotici, zvišani ravni kreatinina v serumu in akutni ledvični odpovedi.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Simptomi: Najizrazitejša pričakovana znaka prevelikega odmerjanja telmisartana sta hipotenzija in tahikardija; poročali so tudi o bradikardiji, omotici, zvišani ravni kreatinina v serumu in akutni ledvični odpovedi.
Symptoms: The most prominent manifestations of telmisartan overdose were hypotension and tachycardia; bradycardia, dizziness, increase in serum creatinine, and acute renal failure have also been reported.
Simptomi: Najizrazitejša znaka prevelikega odmerjanja telmisartana sta hipotenzija in tahikardija; poročali so tudi o bradikardiji, omotici, zvišani ravni kreatinina v serumu in akutni ledvični odpovedi.
Synagis 100 mg powder and solvent for solution for injection
Synagis 100 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 100 mg powder and solvent for solution for injection Palivizumab
Synagus 100 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 100 mg vial label
Synagis 100 mg – nalepka na viali
Synagis 100 mg/ml solution for injection
Synagis 100 mg/ml raztopina za injiciranje
Synagis 100 mg/ml solution for injection
Synagis 100 mg/ml raztopina za injiciranje palivizumab
Synagis 100 mg/ml solution for injection 0.5 ml vial Synagis 100 mg/ml solution for injection 1.0 ml vial
Synagis 100 mg/ml raztopina za injiciranje 0,5 ml viala Synagis 100 mg/ml raztopina za injiciranje 1 ml viala
Synagis 100 mg/ml solution for injection Palivizumab
Synagis 100 mg/ml raztopina za injiciranje palivizumab
Synagis 50 mg powder and solvent for solution for injection
Synagis 50 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 50 mg powder and solvent for solution for injection Palivizumab
Synagis 50 mg prašek in vehikel za raztopino za injiciranje palivizumab
Synagis 50 mg vial label
Synagis 50 mg – nalepka na viali
Synagis is a medicine to help protect your child from getting severe RSV illness
Zdravilo Synagis je zdravilo, ki otroka pomaga zaščititi pred hudo obliko bolezni RSV.
Synagis is presented as a powder and solvent for solution for injection (100 mg of powder in vial) + 1 ml of solvent in ampoule - Pack size of 1.
Zdravilo Synagis sestavljata prašek in vehikel za raztopino za injiciranje (100 mg praška v viali) + 1 ml vehikla v ampuli – pakiranje vsebuje 1 vialo in 1 ampulo.
Synagis is presented as a powder and solvent for solution for injection (50 mg of powder in vial) + 1 ml of solvent in ampoule - Pack size of 1.
Zdravilo Synagis sestavljata prašek in vehikel za raztopino za injiciranje (50 mg praška v viali) + 1 ml vehikla v ampuli – pakiranje vsebuje 1 vialo in 1 ampulo.
Synagis may cause serious side effects including: severe allergic reactions, such reactions may be life threatening or fatal (see "Your child should not be given Synagis" for a list of signs and symptoms). unusual bruising or groups of tiny red spots on the skin.
Zdravilo Synagis lahko povzroči resne neželene učinke, ki vključujejo: hudo alergijsko reakcijo; take reakcije lahko ogrozijo življenje ali so smrtne (glejte ''Otrok ne sme dobiti zdravila Synagis'' za seznam znakov in simptomov). nenavadne modrice ali skupine majhnih rdečih pik na koži.
Synagis may cause serious side effects including: severe allergic reactions, such reactions may be life-threatening or fatal (see "Your child should not be given Synagis" for a list of signs and symptoms). unusual bruising or groups of tiny red spots on the skin.
Zdravilo Synagis lahko povzroči resne neželene učinke, ki vključujejo: hudo alergijsko reakcijo; take reakcije lahko ogrozijo življenje ali so smrtne (glejte poglavje ''Otrok ne sme dobiti zdravila Synagis'' za seznam znakov in simptomov). nenavadne modrice ali skupine majhnih rdečih pik na koži.
Synagis may cause serious side effects including: severe allergic reactions, such reactions may be life-threatening or fatal (see “Your child should not be given Synagis” for a list of signs and symptoms). unusual bruising or groups of tiny red spots on the skin.
Zdravilo Synagis lahko povzroči resne neželene učinke, ki vključujejo: hudo alergijsko reakcijo; take reakcije lahko ogrozijo življenje ali so smrtne (glejte ''Otrok ne sme dobiti zdravila Synagis'' za seznam znakov in simptomov). nenavadne modrice ali skupine majhnih rdečih pik na koži.
Synagis must not be used in people who are hypersensitive (allergic) to palivizumab, any of the other ingredients or other ‘humanised’ monoclonal antibodies.
Zdravila Synagis ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) palivizumab, katero koli drugo sestavino zdravila ali druge vrste humaniziranih monoklonskih protiteles.
Synagis Water for injections ampoule label
Synagis voda za injekcije – nalepka na ampuli
Syncope (fainting)
inkopa (omedlevanje)
Syncope (G3/4: 0%); Neurotoxicity (G3/4: 0%);
sinkopa (S3/4: 0 %), nevrotoksičnost (S3/4: 0%); somnolenca (S3/4:
Syncope and retinopathy have been reported in some patients taking INCIVO and should be considered when assessing a patient’s ability to drive or operate machines.
Pri nekaterih bolnikih, ki so jemali zdravilo INCIVO, so poročali o sinkopi in retinopatiji, kar je treba upoštevati pri oceni bolnikove sposobnosti za vožnjo in upravljanje s stroji.
Syncope Loss of consciousness1
sinkopa izguba zavesti1
Syncope may involve risks of falls or accidents, which could result in serious harm (see sections 4.8 and 4.7)
Sinkopa lahko povzroči nevarnost padcev ali nezgod, lahko z resnimi poškodbami (glejte poglavji 4.8 in 4.7)
Syncope or vasovagal responses to injection, localised hypoaesthesia
Sinkopa ali vazovagalni odziv na injekcijo, omejena hipestezija.
Syncope or vasovagal responses to injection, sometimes accompanied by tonic-clonic movements (see section 4.4)
sinkopa ali vazovagalni odzivi na injekcijo, včasih s spremljajočimi tonično-kloničnimi gibi (glejte poglavje 4.4)
Syncope Seizure Amnesia
sinkopa krči amnezija
Syncope Seizure Extrapyramidal disorder Dysarthria Restless legs syndrome
inkopa, napadi krčev, ekstrapiramidni simptomi, dizartrija, sindrom nemirnih nog
Syncope Unresponsiveness Loss of consciousness
sinkopa neodzivnost izguba zavesti
Syncope, bradycardia and atrioventricular block
Sinkopa, bradikardija in atrioventrikularni blok
syncope, cerebrovascular accident, increase in signs and symptoms of myasthenia gravis, paraesthesia, cerebral ischaemia
sinkopa, cerebrovaskularni dogodki, povečanje znakov in simptomov miastenije gravis, parestezija, cerebralna ishemija
syncope, cerebrovascular accident, increase in signs and symptoms of myasthenia gravis, paresthaesia, cerebral ischaemia
sinkopa, cerebrovaskularni dogodki, povečanje znakov in simptomov miastenije gravis, parestezija, cerebralna ishemija
syncope, headache
sinkopa, glavobol
Syncope, headache, dizziness1.
inkopa, glavobol, omotičnost1
Syncope, memory impairment, disturbance in attention, dreamy state, restless legs syndrome, poor quality sleep, paraesthesia
sinkopa, težave s spominom, motnje pozornosti, zaspanost , sindrom nemirnih nog, šibek spanec, parestezija
syncope, migraine, tremor, sleep disturbances multiple sclerosis
sinkopa, migrena, tremor, motnje spanja multipla skleroza
Syncope, paraesthesia Insomnia, sleep disorders
Redki: nespečnost, motnje spanja
Syncope, paraesthesia, somnolence, dizziness
sinkopa, parestezije, zaspanost, vrtoglavost
Syncope, stupor, myoclonus, loss of consciousness, psychomotor hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, mental impairment, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, malaise
sinkopa, stupor, mioklonus, izguba zavesti, psihomotorična hiperaktivnost, diskinezija, posturalna omotica, intencijski tremor, nistagmus, kognitivne motnje, poslabšanje mentalnih sposobnosti, motnje govora, hiporefleksija, hiperestezija, pekoč občutek, agevzija, splošno slabo počutje
Syncope, Tremor Paraesthesia
sinkopa, tremor, mravljinčenje
Syncope/loss of consciousness
inkopa/izguba zavesti
Syncope1, 4
sinkopa1, 4
Syncope1,4
sinkopa1, 4
Syncope2 Blood pressure increase3
zvišan krvni tlak
Syncope2 Hypertension3,7
tomatitis hematohezija
Syncope§ (see section 4.4) Hypotension*
sinkopa § (glejte poglavje 4.4) hipotenzija
syndrome
obsevanju
syndrome
osteonekroza
syndrome (see section
(glejte
Syndrome and toxic
in toksična
syndrome neonatal (see section 4.6)
Odtegnitveni sindrom pri novorojenčku (glejte poglavje 4.6)
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) a
sindrom neustreznega izločanja antidiuretičnega hormona (SIADH)a
Syndrome) 7
sindrom) 7
syndrome**
eritrodisestezija
syndrome, photosensitivity
Zelo redki
syndromea
hiperurikemija
Synergistic antiretroviral activity was observed when human T–lymphoid cells infected with the LAI variant of HIV–1 were incubated with indinavir and either zidovudine, didanosine, or NNRTIs.
Človeške T-limfoidne celice, okužene z LAI različico HIV-1, so inkubirali z indinavirjem v kombinaciji z zidovudinom, didanozinom ali NNRTI-ji in opazili sinergistično protiretrovirusno delovanje.
Synflorix 2+1 schedule
Synflorix Shema 2+1
Synflorix 3+1 schedule
Synflorix Shema 3+1
Synflorix can be given concomitantly with any of the following monovalent or combination vaccines [including DTPa-HBV-IPV/Hib and DTPw-HBV/Hib]: diphtheria-tetanus-acellular pertussis vaccine (DTPa), hepatitis B vaccine (HBV), inactivated polio vaccine (IPV), Haemophilus influenzae type b vaccine (Hib), diphtheria-tetanus-whole cell pertussis vaccine (DTPw), measles-mumps-rubella vaccine (MMR), varicella vaccine (V), meningococcal serogroup C conjugate vaccine (CRM197 and TT conjugates), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (TT conjugate), oral polio vaccine (OPV) and oral rotavirus vaccine.
Synflorix je mogoče uporabiti sočasno s katerimkoli od naslednjih monovalentnih ali kombiniranih cepiv [vključno z DTPa-HBV-IPV/Hib in DTPw-HBV/Hib]: cepivom proti davici, tetanusu in oslovskemu kašlju (brezcelično) (DTPa), cepivom proti hepatitisu B (HBV), inaktiviranim cepivom proti poliu (IPV), cepivom proti Haemophilus influenzae tipa b (Hib), cepivom proti davici, tetanusu in oslovskemu kašlju (polnocelično) (DTPw), cepivom proti ošpicam, mumpsu in rdečkam (MMR), cepivom proti varicelli (V), konjugiranim cepivom proti meningokokom serološke skupine C (konjugati CRM197 in TT), konjugiranim cepivom proti meningokokom serološke skupine A, C, W- 135 in Y (konjugati TT), peroralnim cepivom proti poliu (OPV) in peroralnim cepivom proti rotavirusom.
Synflorix contains small amounts of polysaccharides (a type of sugar) extracted from the ‘capsule’ that surrounds the S. pneumoniae bacterium.
Cepivo Synflorix vsebuje majhne količine polisaharidov (vrste sladkorja), pridobljenih iz ovojnice, ki obdaja bakterijo S. pneumoniae.
Synflorix contains the polysaccharides from 10 different types of S. pneumoniae (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).
Cepivo Synflorix vsebuje polisaharide iz 10 različnih vrst bakterije S. pneumoniae (serotipe 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F in 23F).
Synflorix does not provide protection against other micro- organisms.
Cepivo Synflorix ne nudi zaščite proti ostalim mikroorganizmom.
Synflorix is a pneumococcal conjugate vaccine.
Synflorix je konjugirano pnevmokokno cepivo.
Synflorix is a turbid white suspension.
Cepivo Synflorix je motna bela suspenzija.
Synflorix is a vaccine.
Zdravilo Synflorix je cepivo.
Synflorix is available in pre-filled syringes with or without needles in packs of 1, 10 or 50.
Cepivo Synflorix je na voljo v napolnjenih injekcijskih brizgah (z iglami ali brez igel) v pakiranjih po 1, 10 ali 50.
Synflorix is available in vials for 2 doses in a pack of 100.
Cepivo Synflorix je na voljo v vialah za 2 odmerka v pakiranjih po 100.
Synflorix is available in vials in packs of 1, 10 or 100
Cepivo Synflorix je na voljo v vialah v pakiranjih po 1, 10 ali 100.
Synflorix is indicated for use in children aged from 6 weeks up to 5 years.
Cepivo Synflorix je indicirano pri otrocih v starosti od 6 tednov do 5 let.
Synflorix is used to protect infants and children aged between six weeks and five years against invasive disease, pneumonia (infection of the lungs) and acute otitis media (infection of the middle ear) caused by S. pneumoniae.
Cepivo Synflorix se uporablja za zaščito dojenčkov in otrok, starih od šest tednov do pet let, proti invazivni bolezni, pljučnici in akutnemu vnetju srednjega ušesa (otitis media), ki ga povzroči bakterija
Synflorix may not work as well if your child is taking medicines that affect the immune system to fight infection.
Če otrok dobiva zdravila, ki poslabšajo sposobnost imunskega sistema za premagovanje okužb, cepivo Synflorix morda ne bo delovalo enako dobro.
Synflorix must not be used in children who have a severe fever, but it can be given in children who have a mild infection such as a cold.
Cepivo Synflorix se ne sme uporabljati pri otrocih z močno povišano telesno temperaturo, lahko pa so cepljeni otroci z blažjo okužbo, kot je prehlad.
Synflorix suspension for injection
Synflorix suspenzija za injiciranje
Synflorix suspension for injection IM
Synflorix suspenzija za injiciranje i.m.
Synflorix suspension for injection in multidose container Pneumococcal polysaccharide conjugate vaccine (adsorbed)
Synflorix suspenzija za injiciranje v večodmernem vsebniku konjugirano, adsorbirano cepivo s pnevmokoknimi polisaharidi
Synflorix suspension for injection in pre-filled syringe IM
Synflorix suspenzija za injiciranje v napolnjeni injekcijski brizgi i.m.
Synflorix suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (adsorbed)
Synflorix suspenzija za injiciranje v napolnjeni injekcijski brizgi Konjugirano, adsorbirano cepivo s pnevmokoknimi polisaharidi
Synflorix suspension for injection in pre-filled syringe Synflorix suspension for injection
Synflorix suspenzija za injiciranje v napolnjeni injekcijski brizgi Synflorix suspenzija za injiciranje
Synflorix was also investigated in a large study involving around 24,000 children aged between 6 and 16 weeks that focussed mainly on the vaccine’s benefit in preventing community acquired pneumonia.
Cepivo Synflorix so proučevali tudi v veliki študiji, v katero je bilo vključenih 24 000 otrok, starih od 6 do 16 tednov, namenjena pa je bila ugotavljanju koristi cepiva pri preprečevanju pljučnice, pridobljene zunaj bolnišnice.
Synflorix was also shown to reduce the occurrence of pneumonia.
Cepivo Synflorix se je prav tako izkazalo za učinkovito pri zmanjševanju pojava pljučnice.
Synflorix was as effective as the comparator in triggering the production of antibodies against five of the polysaccharides that the two vaccines shared in common (4, 9V, 14, 18C and 19F), but it was less effective than the comparator for two (6B and 23F).
Cepivo Synflorix je bilo enako učinkovito kot primerjalno cepivo pri sprožitvi tvorbe protiteles proti petim polisaharidom, ki so jima skupni (4, 9V, 14, 18C in 19F), vendar je bilo manj učinkovito od primerjalnega cepiva pri dveh polisaharidih (6B in 23F).
Synjardy
Zdravilo Synjardy
Synjardy 12.5 mg/1,000 mg film-coated tablets empagliflozin/metformin hydrochloride
Synjardy 12,5 mg/1000 mg filmsko obložene tablete empagliflozin/metforminijev klorid
Synjardy 12.5 mg/1,000 mg tablets empagliflozin/metformin HCL
Synjardy 12,5 mg/1000 mg tablete empagliflozin/metforminijev klorid
Synjardy 12.5 mg/850 mg film-coated tablets
Synjardy 12,5 mg/850 mg filmsko obložene tablete
Synjardy 12.5 mg/850 mg film-coated tablets empagliflozin/metformin hydrochloride
Synjardy 12,5 mg/850 mg filmsko obložene tablete empagliflozin/metforminijev klorid
Synjardy 12.5 mg/850 mg tablets empagliflozin/metformin HCL
Synjardy 12,5 mg/850 mg tablete empagliflozin/metforminijev klorid
Synjardy 5 mg/1,000 mg film-coated tablets empagliflozin/metformin hydrochloride
Synjardy 5 mg/1000 mg filmsko obložene tablete empagliflozin/metforminijev klorid
Synjardy 5 mg/1,000 mg tablets empagliflozin/metformin HCL
Synjardy 5 mg/1000 mg tablete empagliflozin/metforminijev klorid
Synjardy 5 mg/850 mg film-coated tablets and Synjardy 5 mg/1,000 mg film-coated tablets Tablet core
Synjardy 5 mg/850 mg filmsko obložene tablete in Synjardy 5 mg/1000 mg filmsko obložene tablete Jedro tablete
Synjardy 5 mg/850 mg film-coated tablets empagliflozin/metformin hydrochloride
Synjardy 5 mg/850 mg filmsko obložene tablete empagliflozin/metforminijev klorid
Synjardy 5 mg/850 mg tablets empagliflozin/metformin HCL
Synjardy 5 mg/850 mg tablete empagliflozin/metforminijev klorid
Synjardy empagliflozin / metformin
Synjardy empagliflozin/metformin
Synjardy is a diabetes medicine that is used, in combination with diet and exercise, in adults with type 2 diabetes to improve the control of their blood glucose (sugar) levels.
Zdravilo Synjardy je zdravilo za zdravljenje sladkorne bolezni, ki se v kombinaciji s prilagojeno prehrano in telesno vadbo uporablja pri odraslih s sladkorno boleznijo tipa 2 za boljše uravnavanje ravni glukoze (sladkorja) v krvi.
Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control
Zdravilo Synjardy je indicirano za zdravljenje sladkorne bolezni tipa 2 pri odraslih bolnikih, starih 18 let in več, za izboljšanje urejenosti glikemije kot dopolnilo k dieti in telesni aktivnosti:
Synjardy is used in the following groups:
Zdravilo Synjardy se uporablja pri naslednjih skupinah bolnikov:
Synovial sarcoma subgroups
Podskupine sinovijskega sarkoma
Synperonic NCA 830 Dimethyl sulfoxide Gamma-hexalactone
Synperonic NCA 830 Dimetilsulfoksid Gama-heksalakton
Syphilis Seroreactivity, N (%)
Seroreakcija sifilisa, N (%)
syringe
brizga
syringe
EU/1/01/184/011
syringe
injekcijska
SYRINGE
INJEKCIJSKA BRIZGA
syringe (glass)
(steklo)
syringe (glass)
brizga (steklena)
syringe (glass)
injekcijska
Syringe (glass)
Injekcijska brizga (steklena)
syringe (glass) in a pre-filled pen (SensoReady)
injekcijska brizga (steklena) v napolnjenem injekcijskem peresniku (SensoReady)
syringe (glass) in pre-filled pen (ClickJect)
injekcijska brizga (steklo) v napolnjenem injekcijskem peresniku (ClickJect)
syringe (glass) pre-filled
napolnjena
syringe (PET)
brizga (PET)
syringe + 1 separate needle
injekcijska brizga + 1
syringe + 2 separate
injekcijska brizga +2
syringe and draw up some air into the syringe by pulling the plunger to approximately the 1 ml mark.
potegnite vanjo nekaj zraka, tako da potisnete bat približno do oznake 1 ml.
Syringe barrel Syringe cap
Pokrovček
Syringe barrel Syringe cap
Valj brizge Pokrovček brizge
Syringe BEFORE USE Syringe AFTER USE
Injekcijska brizga PRED UPORABO Injekcijska brizga PO UPORABI
Syringe body plunger with medicine
Ohišje brizge z zdravilom
Syringe cap
pokrovček brizge
Syringe cap
pokrovček injekcijske brizge
Syringe cap 0.05 ml dose mark Finger grip
pokrovček odmerna oznaka držalo za brizge za 0,05 ml prste
Syringe containing your medicine being attached to a new needle
Nameščanje nove igle na brizgo z zdravilom
Syringe guard
zapiralo brizge
Syringe label
Nalepka na brizgi
SYRINGE LABEL FOR SOLVENT
NALEPKA NA BRIZGI ZA VEHIKEL
SYRINGE LABEL – 150 mg
NALEPKA BRIZGE – 150 mg
SYRINGE LABEL – 75 mg
NALEPKA BRIZGE – 75 mg
Syringe labelling
Brizga
Syringe labelling
Označevanje brizge
Syringe Needle Retracts After Use
Igla injekcijske brizge se po uporabi uvleče
Syringe Needles (2)
injekcijska brizga igli (2)
SYRINGE OF SOLVENT
INJEKCIJSKA BRIZGA Z VEHIKLOM
Syringe plunger
Bat brizge
Syringe plunger
Bat brizge Valj brizge
Syringe with a manual needle protection system showing security sleeve being pulled over needle AFTER USE
Injekcijska brizga z ročnim sistemom za zaščito igle.
Syringe with an attached needle
Brizga s pritrjeno iglo
Syringe with an attached needle and a needle protection device
Brizga s pritrjeno iglo in pripomočkom za zaščito igle
Syringe with an unattached needle
Brizga z nepritrjeno iglo
syringe with attached
injekcijska brizga z
syringe without needle
injekcijska brizga brez igle
syringes
brizg
syringes
brizge
syringes
EU/1/01/184/022
syringes
injekcijskih brizg
syringes
nastavkom
syringes + 10 separate
injekcijskih brizg + 10
syringes + 20 separate
injekcijskih brizg + 20
syringes + 4 injection needles
brizge + 4
syringes + 40 separate
injekcijskih brizg + 40
Syringes are embossed with graduation rings in order to enable partial use if required.
Brizge imajo merilne oznake v obliki obroča, ki omogoča delno uporabo, če je to potrebno.
Syringes must not be used more than once.
Brizge je dovoljeno uporabiti le enkrat.
syringes with attached
injekcijskih brizg z
syringes without needle
injekcijskih brizg brez igel
Syrup.
sirup
system
istema
system
sistemom
system disorders
Bolezni imunskega sistema
System error
istemska napaka
System error
sistemska napaka
System Order Class
Organski sistem
System Organ
MedDRA (SOC)
System organ
Organski sistem
System Organ Class
avtoimunski hepatitis1)
System organ class
Bolezni
System organ class
Bolezni imunskega sistema
System organ class
Bolezni prebavil
System Organ Class
Bolezni sečil
System Organ Class
elektrokardiogram,
System Organ Class
epistaksa
System organ class
hemoroidi
System organ class
impotenca
System organ class
izpuščaj, akne
SYSTEM ORGAN CLASS
KLASIFIKACIJA PO ORGANSKIH SISTEMIH
System Organ Class
Organski
System organ class
Organski siste m
System organ class
Organski sistem po MedDRA
System organ class
Organski sistem Zelo
System Organ Class
Organski sistemi po MedDRA
SYSTEM ORGAN CLASS
Očesne bolezni
System organ class
pogosti
System Organ Class
povečane
System Organ Class
Razporeditev po organskih sistemih
System organ class
Vrsta organskega sistema
System Organ Class
Zelo pogosti ( 1/10)
System Organ Class
živčnih korenov,
System Organ Class (MedDRA terminology)
Organski sistem (po MedDRA
System Organ Class (SOC)
Organski sistem
System Organ Class (SOC)
Organski sistem (SOC)
System Organ Class (SOC)
Razvrstitev organov po sistemu MedDRA (SOC)
System Organ Class (SOC)
Razvrstitev po organskih sistemih
System Organ Class (SOC)
Razvrstitev po organskih sistemih (SOC)
System Organ Class (SOC)
SKELETNEGA SISTEMA
System Organ Class (SOC, MedDRA)
Bolezni živčevja
System Organ Class (SOC, MedDRA)
Organski sistem
System Organ Class Adverse drug reactions Infections and infestations
Organski sistem Neželeni učinki Infekcije in okužbe
System Organ Class by MedDRA
Organski sistem po MedDRA
System Organ Class Frequency
Pogostnost
System organ class Frequency Adverse reaction
Organski sistem Pogostnost Neželeni učinek
System organ class Infections and infestations
Infekcijske in parazitske bolezni
System organ class MedDRA
Organski sistemi po MedDRA
System Organ Class Preferred Term
Organski sistem izraz po MedDRA
System Organ Class[A1]
Organski sistem
System Organ Classes (SOC)
Organski sistemi
System Organ Classification Common Uncommon Rare
Organski sistem Pogosti Občasni Redki
System Organ Classification Infections and Infestations
Organski sistem Razvrstitev Infekcijske in parazitske bolezni
System/Organ Class
Organski sistemi
Systemic
istemski
Systemic
istemskimi